{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Primary site is defined as the original, or first site that the cancer developed in the body. In this study, primary sites within the head and neck included squamous cancers of the larynx, oral cavity, oropharynx, hypopharynx.Complete response rate in patients treated with 2 cycles of induction Docetaxel and Carboplatin with low dose fractionated radiation therapy (LDFRT) will be compared to those treated with chemotherapy alone. CRR was determined Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Where possible, surgeon also evaluated primary site and provided response assessment.","groups":[{"description":"Low dose fractionated radiation - 80cGy with chemotherapy\n\nLow dose fractionated radiation - 80cGy with chemotherapy: Chemotherapy + 80 cGy of RT","id":"OG000","title":"Chemotherapy Plus Radiation Therapy"},{"description":"Chemotherapy only\n\nDocetaxel and Carboplatin AUC 6: Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation","id":"OG001","title":"Chemotherapy Without Radiation"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 50 days","title":"Primary Site Complete Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}